Vasopressin antagonism for decompensated right-sided heart failure
| Autor: | Zackary D. Goff, Anuradha Godishala, Paul J. Hauptman, Susan M. Joseph, Jerrica E. Shuster, John T. Chibnall, Andrija Vidic |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Inotrope medicine.medical_specialty medicine.drug_class medicine.medical_treatment Tolvaptan Urology Renal function 030204 cardiovascular system & hematology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Humans 030212 general & internal medicine Retrospective Studies Heart Failure Creatinine business.industry Furosemide Stroke Volume Benzazepines Middle Aged Diuresis Treatment Outcome chemistry Ventricular Function Right Female Diuretic Conivaptan Cardiology and Cardiovascular Medicine business Antidiuretic Hormone Receptor Antagonists Vasopressin Antagonists Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Cardiology. 274:245-247 |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2018.08.036 |
| Popis: | Background Targeted treatment for decompensated right heart failure (RHF) with or without left heart failure is lacking. Vasopressin antagonists (vaptans) may offer an option by increasing urine output and fluid mobilization when used in acute decompensated RHF without impacting blood pressure or renal function, both common complications of loop diuretics. Methods and results We searched electronic medical records from 2 institutions over 4 years for patients with RHF treated with vaptans. Urine output, creatinine, BUN and sodium, 1 day pre- versus 1 day post-vaptan initiation were compared. Baseline (admission) pre-vaptan values for patients with RHF who met inclusion criteria (n = 112) were RAP, median (interquartile range) = 19 (13–24) mmHg; cardiac index, mean ± standard deviation = 1.8 ± 0.4 L/min/m2; BNP, 1078 (523–1690) pg/ml; creatinine clearance of 51 (39–69) ml/min, BUN, 37 (26–54) mg/dl, and serum [Na+] 132 (126–135) mEq/L. Most patients (n = 103/112) received intravenous inotrope (prior to vaptan, n = 91). Overall length of stay was 27 (16–43) days. Vaptan treatment (90% tolvaptan, 10% conivaptan) was associated with increased 24 h urine output, 1517 (906–2394) vs 2337 (1425–3744) mL, p = 0.005, and [Na+], 127 (124–130) vs 130 (126–135) mEq/L, p = 0.001, without significant change in Cr or BUN. Furosemide IV dose equivalent decreased or remained unchanged in 75% of patients at 24 h and 64% at 72 h compared to the 24 h prior to vaptan use. Conclusion Vaptans were associated with a significant increase in urine output and serum sodium with an apparent reduction or stabilization of furosemide equivalent dosing in the early treatment period in patients with decompensated RHF. Vaptans may offer a management option for patients failing conventional diuretic-based treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect